Calcium kinetics in glycogen storage disease type 1a.

Glycogen storage disease type 1a (Von Gierke's disease) is one of the more common glycogen storage diseases (GSD). GSD 1a patients can have severe idiopathic osteopenia, often beginning at a young age. Since calcium tracer studies offer a sensitive probe of the bone microenvironment and of calcium deposition, kinetics might be disturbed in patients with GSD 1a. Plasma dilution kinetics obtained using the stable isotope 42Ca are shown in this paper to be quite different between GSD 1a patients and age-matched controls. Comparison of kinetic parameters in these two populations is made using a new binding site model for describing calcium dynamics at the plasma-bone interface. This model describes reversible binding of calcium ions to postulated short-term and long-term sites by a retention probability density function psi (t). Using this analysis, adult GSD subjects exhibited a significant decrease (P = 0.023) in the apparent half-life of a calcium ion on the longer-term site compared with controls. The general theory of calcium tracer dilution kinetics is then discussed in terms of a new model of short-term calcium homeostasis recently proposed by Bronner and Stein [5].

Mutations in the glucose-6-phosphatase gene are associated with glycogen storage disease types 1a and 1aSP but not 1b and 1c.

Glycogen storage disease (GSD) type 1, which is caused by the deficiency of glucose-6-phosphatase (G6Pase), is an autosomal recessive disease with heterogenous symptoms. Two models of G6Pase catalysis have been proposed to explain the observed heterogeneities. The translocase-catalytic unit model proposes that five GSD type 1 subgroups exist which correspond to defects in the G6Pase catalytic unit (1a), a stabilizing protein (1aSP), the glucose-6-P (1b), phosphate/pyrophosphate (1c), and glucose (1d) translocases. Conversely, the conformation-substrate-transport model suggests that G6Pase is a single multifunctional membrane channel protein possessing both catalytic and substrate (or product) transport activities. We have recently demonstrated that mutations in the G6Pase catalytic unit cause GSD type 1a. To elucidate whether mutations in the G6Pase gene are responsible for other GSD type 1 subgroups, we characterized the G6Pase gene of GSD type 1b, 1c, and 1aSP patients. Our results show that the G6Pase gene of GSD type 1b and 1c patients is normal, consistent with the translocase-catalytic unit model of G6Pase catalysis. However, a mutation in exon 2 that converts an Arg at codon 83 to a Cys (R83C) was identified in both G6Pase alleles of the type 1aSP patient. The R83C mutation was also demonstrated in one homozygous and five heterogenous GSD type 1a patients, indicating that type 1aSP is a misclassification of GSD type 1a. We have also analyzed the G6Pase gene of seven additional type 1a patients and uncovered two new mutations that cause GSD type 1a.

Determination of fractional absorption of dietary calcium in humans.

Four dual-isotopic label methods for determining true fractional absorption of dietary calcium were compared in 23 subjects. The ratio of the integrals of oral label in a 24-h pooled urine to intravenous label in the same urine is called alpha 24h and was taken as the standard against which the others were compared. alpha Spot is the ratio of the fraction of oral label to the fraction of intravenous label in a single urine specimen; alpha Lag is the ratio of the level of oral label in blood 4 h after administration to the level of intravenous label in blood 2 h after administration. alpha Dec is obtained by deconvoluting response to the intravenous label from the response to the oral tracer. Results were as follows: alpha 24h = 0.273 +/- 0.124, alpha Dec = 0.300 +/- 0.101 (n = 14), alpha Spot = 0.359 +/- 0.179, and alpha Lag = 0.271 +/- 0.103. The Bland-Altman approach for comparison of methods was used to show that results for alpha Spot and alpha Lag can be expected, with a 95% confidence limit, to differ from the value of alpha 24h by 60 and 69%, respectively. The results for alpha Dec were shown to be not only indistinguishable from alpha 24h but identical from a theoretical perspective.

Mutations in the glucose-6-phosphatase gene that cause glycogen storage disease type 1a.

Glycogen storage disease (GSD) type 1a is caused by the deficiency of D-glucose-6-phosphatase (G6Pase), the key enzyme in glucose homeostasis. Despite both a high incidence and morbidity, the molecular mechanisms underlying this deficiency have eluded characterization. In the present study, the molecular and biochemical characterization of the human G6Pase complementary DNA, its gene, and the expressed protein, which is indistinguishable from human microsomal G6Pase, are reported. Several mutations in the G6Pase gene of affected individuals that completely inactivate the enzyme have been identified. These results establish the molecular basis of this disease and open the way for future gene therapy.

Type I glycogen storage disease: nine years of management with cornstarch.

Long-term effects of cornstarch (CS) therapy on biochemical values and physical growth in children with type I glycogen storage disease (GSD I) were compared to those of children receiving continuous nocturnal nasogastric glucose feedings (CNG). Only patients who had received more than 5 years of dietary therapy (either CS or CNG) were evaluated. Six patients (five female, age 13.5 years +/- 1.3, range 11.7-16.5 years) received CS (1.75-2.5 g/kg, four times daily) and seven patients (five female, age 9.6 +/- 2.5 years, range 7.3-14.8 years) received CNG. Blood glucose, lactate, cholesterol and triglyceride levels were not significantly different between the two methods of treatment. All patients maintained linear growth rates normal for their age. The standard deviation score of height after 6.7 +/- 1.6 years (range 5-9 years) of CS treatment was -1.29 +/- 0.59 and after 8.8 +/- 2.4 years (range 7-14 years) of CNG was -1.24 +/- 0.63. These values did not differ significantly from each other or from the target height, an estimate of genetic potential for height as determined from parental heights. With the exceptions of diarrhea, increased flatulence and excess weight gain, there were no adverse effects of CS after 9 years of treatment. Our data suggests that cornstarch is a simple, effective and safe therapy for GSD I.

Developmental changes in calcium kinetics in children assessed using stable isotopes.

Total exchangeable calcium pool size (TEP) and bone calcium accretion rate (Vo+) were measured using stable isotopes in healthy children and young adults. 42Ca or 46Ca was given intravenously to 10 children aged 10 months to 14 years and 3 women aged 23-33 years. Calcium kinetic parameters were determined using a two- or three-exponential curve of the resultant serum and urine tracer excesses. These data were compared with previously reported (radiotracer) kinetic studies of 21 children and 5 adults without known bone disease. Current results are comparable to those previously obtained, and the data from all studies were analyzed together. Total Vo+ was significantly greater in children aged 3-16 years than in adults (2.8 +/- 1.6 versus 0.7 +/- 0.2 g/day, p less than 0.01). Both TEP and Vo+ were significantly correlated to age independently of variations in body weight (p less than 0.01 for each). The ratio ko+ = Vo+/TEP was greater in children than adults (0.36 +/- 0.15 versus 0.12 +/- 0.03 day-1, p less than 0.001). These data demonstrate increased bone flow of calcium associated with increases in exchangeable calcium pools in children compared to adults. Vo+ and TEP may be maximum in early adolescence, associated with peak rates of net calcium accretion. The use of stable isotopes permits the safe evaluation of calcium kinetics in patients of all ages.

Stable isotopic measurement of endogenous fecal calcium excretion in children.

Using a stable isotopic technique in which 42Ca was administered via a bolus injection, we measured endogenous fecal calcium excretion, Vf, in five healthy children, aged 3-14 years. The Vf averaged 1.4 +/- 0.4 mg/kg/day, and was lower than urinary Ca excretion (Vu) in four of the five children. These results for Vf are consistent with previously reported results for Vf in healthy adults and much lower than those reported in premature infants. These results may be useful in understanding developmental changes in Ca metabolism and in interpreting dual tracer Ca isotope studies in children.

Renal disease in type I glycogen storage disease.

Although kidney enlargement occurs in Type I glycogen storage disease, renal disease has not been considered a major problem. Death from renal failure in three patients known to us prompted a study of renal function in this disorder. Of the 38 patients with Type I glycogen storage disease under our care, the 18 children under 10 years old had normal renal function. Fourteen of the 20 older patients (13 to 47 years) had disturbed renal function, manifested by persistent proteinuria; many also had hypertension, hematuria, or altered creatinine clearance. Progressive renal insufficiency developed in 6 of these 14 patients, leading to three deaths from renal failure. At the onset of proteinuria, creatinine clearance was increased in seven patients (3.05 +/- 0.68 ml per second per 1.73 m2 of body-surface area; range, 2.47 to 4.13 [normal range, 1.33 to 2.33 ml per second per 1.73 m2]). Renal biopsies were performed in three patients after an average of 10 years of proteinuria. All three biopsies demonstrated focal segmental glomerulosclerosis in various stages of progression. Our data suggest that chronic renal disease is a frequent and potentially serious complication of Type I glycogen storage disease. In addition to treating hypoglycemia vigorously, physicians should monitor renal function carefully in patients with this disorder.

The daily profile of plasma melatonin in obese and Prader-Willi syndrome children.

Daily plasma melatonin profiles were determined by RIA in exogenously obese and Prader-Willi syndrome children. The melatonin RIA was validated for use in human plasma by evaluating melatonin immunoreactivity in the resultant eluate fractions of a high performance liquid chromatogram of a chloroform-extracted pooled human plasma sample. Melatonin immunoreactivity in the plasma profile occurred only in the fraction that corresponded to the chromatographic position of authentic melatonin. Exogenously obese patients had plasma melatonin profiles characterized by low levels during the day (20-30 pg/ml plasma) and high levels at night (65-130 pg/ml plasma). The plasma melatonin profile did not vary as a function of weight or pubertal status. Prader-Willi syndrome patients had similar melatonin profiles to those of exogenously obese patients. Although the Prader-Willi children had a delayed onset of puberty, the plasma melatonin profile was unaltered. These data indicate that plasma melatonin may not play a role in the onset of puberty. However, the daily melatonin profile is a temporally precise hormonal rhythm in humans.

Age-related changes in the free amino acid pool of rat lens.

Quite disparate values have been reported by various investigators for the concentrations of free amino acids in the normal rat lens. To test the possibility that the apparent discrepancies could result from age- or strain-related effects, assays were made on both weanling and mature specimens from two common laboratory strains of rats. Althoug, the levels of free amino acids in the plasma were very similar in all groups, the total free amino acid concentration in the lenses of weanling rats was almost double that found in mature rats. Individual amino acids showed quite varied patterns of age-related changes in concentration. Although there is limited evidence that strain-related differences in the amino acid pool may also exist, it was concluded that age-related alterations pro0ably account for most of the variation present in the previously reported values.

Plasma amino acids in patients with the carcinoid syndrome.

Plasma tryptophan (Trp) is reported to be decreased in some patients with the carcinoid syndrome. To determine if the plasma levels of other amino acids are also altered in the carcinoid syndrome, we used a fas-liquid chromatographic method to determine the plasma amino acid concentration of nine patients with the carcinoid syndrome and nine age-matched healthy control subjects. In comparison to the control subjects, the patients with the carcinoid syndrome had decreased plasma concentration of valine (Val), isoleucine (Ile), lysine (Lys), and ornithine (Orn), and an increased plasma concentration of methionine (Met). With the exception of a decrease in urinary excretion of proline (Pro) and hydroxyporline (Hyp), the patients with the carcinoid syndrome had normal quantities of amino acids in their urine. Plasma Met returned to normal when serotonin production by the tumor was reduced 60% by parachlorophenylalanine (PCPA); the other amino acid abnormalities persisted. Further studies are needed to determine the significance of these amino acid abnormalities.

Studies on beta-crystallin from primate lens.

The major beta-crystallin fractions from the human lens and the lenses of other selected primates have been isolated and partially characterized. Primate beta-crystallins, like those of most other mammals, consist of two heterogenous protein fractions (betaH and beta L) of quite different molecular size. Most of the polypeptide chains comprising the betaH and beta L heteropolymers are common to both fractions. Evidence is presented suggesting that primate betaH-crystallin may be smaller than betaH from other vertebrate species. Additionally, human betaH is found to contain a major component on sodium dodecyl sulfate (SDS) electrophoresis which is much larger (about 60,000 daltons) than other beta-crystallin polypeptides. Immunochemical evidence inidcates that some components of primate beta-crystallin have evolved rapidly, although at least one antigenic component is very conservative and gives a reaction of identity with all other vertebrate beta-crystallins studied.

Diagnosis of lipogranulomatosis (Farber disease) by use of cultured fibroblasts.

The enzyme defect in Farber disease, a deficiency of acid ceramidase, has been demonstrated in cultured skin fibroblasts, which provides a means of confirming the diagnosis during life. The assay can also be performed using cultured amniotic fluid cells and is a potential tool for detection of carriers of the disease.